🧬 Cancer Vaccines — Updated Overview (2025)

-

  By Dr. Sk Sabir Rahaman, MBBS, MD (Pharmacology), DFM(Family Medicine), FCFM, CCEBDM, CCLSD

🔹 1. Definition

Cancer vaccines are biological preparations that train the immune system to recognize and attack tumor cells.

They target:

  • Tumor-associated antigens (TAA): present in normal cells but overexpressed in cancers (e.g., AFP in hepatocellular carcinoma, HER2 in breast cancer).

  • Neoantigens: novel proteins created by tumor mutations, unique to cancer cells.

👉 Aim: either prevent cancer (prophylactic vaccines) or treat established cancer (therapeutic vaccines).

🔹 2. Classification

A. Prophylactic (Preventive) Cancer Vaccines

  • Block infection with oncogenic viruses → prevent virus-driven cancers.

  • Examples:

    • HPV vaccines (Gardasil, Cervarix, Gardasil-9) → prevent cervical, vulvar, vaginal, anal, penile, and oropharyngeal cancers.

    • Hepatitis B vaccine → prevents chronic HBV infection, reducing hepatocellular carcinoma risk.

  • ✅ Clinically established, effective, and part of national immunization programs worldwide (including India with HPV rollout).

B. Therapeutic (Treatment) Cancer Vaccines

  • Activate cytotoxic CD8+ T cells and CD4+ helper T cells to kill tumor cells.

  • Examples:

    • Sipuleucel-T (Provenge): FDA-approved (2010) for metastatic prostate cancer.

    • Investigational: peptide vaccines (melanoma), dendritic cell vaccines (DCVax-L), mRNA vaccines (BioNTech/Moderna), personalized neoantigen vaccines.

  • ❗ Still experimental, often combined with checkpoint inhibitors (anti-PD-1, anti-CTLA-4).

🔹 3. Mechanism of Action

  1. Vaccine antigens (TAA/neoantigens) introduced.

  2. Captured by antigen-presenting cells (APCs) like dendritic cells.

  3. Presented via MHC I & II pathways.

  4. T-cell response:

    • CD8+ CTLs → direct tumor killing.

    • CD4+ T-helpers → sustain immune attack.

  5. Immune memory reduces recurrence.

  6. Adjuvants (e.g., GM-CSF, TLR agonists) boost response.

  7. Checkpoint inhibitors added to overcome tumor immune evasion.

🔹 4. Approaches to Cancer Vaccines

  • Whole tumor cell vaccines: killed or modified tumor cells.

  • Peptide/protein vaccines: e.g., gp100 in melanoma.

  • DNA/RNA vaccines: plasmids or mRNA encoding tumor antigens (BioNTech, Moderna).

  • Dendritic cell vaccines: patient’s DCs loaded with antigens (Sipuleucel-T, DCVax-L).

  • Neoantigen-based vaccines: fully personalized based on tumor sequencing.

  • Oncolytic virus-based vaccines: engineered viruses that infect and lyse tumor cells while expressing antigens.

🔹 5. Advantages

  • High specificity for tumor antigens.

  • Induce long-lasting immune memory.

  • Reduce recurrence risk.

  • Scope for precision oncology through personalization.

🔹 6. Limitations

  • Tumor immune evasion (↓ MHC, ↑ TGF-β, IL-10).

  • Tumor heterogeneity → variable antigen expression.

  • Modest efficacy as monotherapy.

  • Costly and time-intensive personalization.

  • Less effective in immunosuppressed patients.

🔹 7. Current Status (2025)

Preventive Vaccines

  • HPV & HBV vaccines: established success.

  • EBV vaccines: in trials for lymphomas & nasopharyngeal carcinoma (not yet approved).

Therapeutic Vaccines

  • Sipuleucel-T → still the only FDA-approved therapeutic vaccine.

  • Neoantigen & mRNA vaccines → Phase II/III trials show encouraging results in melanoma, pancreatic cancer, renal cell carcinoma, and NSCLC.

  • Dendritic cell vaccines (DCVax-L): showing survival benefit in glioblastoma.

  • Combination with checkpoint inhibitors gives best outcomes.

🔹 8. International Perspective

  • Strong pipeline (2024–25): BioNTech, Moderna, GSK leading personalized vaccine trials.

  • Partnerships between pharma & academia are fast-tracking late-phase studies.

  • Early results: better tumor shrinkage and survival when vaccines are combined with immunotherapies.

  • Future trends:

    • Oncolytic viruses with tumor antigens.

    • Personalized mRNA vaccines adapted from COVID-19 platforms.

    • EBV-targeted vaccines for virus-driven cancers.

🔹 9. Indian Perspective

  • Preventive vaccines:

    • Cervavac (Serum Institute, 2022): low-cost quadrivalent HPV vaccine.

    • Govt. planning nationwide HPV rollout to reduce cervical cancer.

  • Manufacturing & Research:

    • Bharat Biotech (2025) set up advanced facilities for gene & cell therapy.

    • Indian pharma (Serum, Bharat, Zydus) investing in next-gen vaccine platforms.

  • Clinical trials:

    • Limited, but growing participation in global therapeutic vaccine research.

    • Primary focus: public health deployment of HPV vaccines.

🔹 10. Future Directions

  • Wider integration of personalized cancer vaccines into standard oncology care.

  • Combination regimens: vaccines + checkpoint inhibitors + chemotherapy.

  • Affordable platforms for global accessibility (key for India & LMICs).

  • Expansion of mRNA and viral vector platforms from infectious disease to cancer.

  • Possible approvals of EBV & neoantigen vaccines within the next decade.

🌟 Spotlight: Russia’s Enteromix mRNA Cancer Vaccine (2025)

At the 2025 St. Petersburg Economic Forum, Russia announced Enteromix, an mRNA cancer vaccine for colorectal cancer, reporting 100% efficacy in early trials (48 patients).

🔬 Key Highlights

  • Uses mRNA technology to encode patient-specific neoantigens.

  • Each dose is personalized using tumor genomic profiling.

  • Reported outcomes: all patients showed tumor shrinkage, no major side effects.

  • Govt. pledge: free access once approved.

⚠️ Caveats

  • Small sample size (48 patients).

  • No peer-reviewed publication yet.

  • Phase II/III validation needed across countries.

  • Logistical hurdles: genomic sequencing + rapid vaccine manufacturing.

🌍 Global & Indian Implications

  • If validated, could revolutionize cancer therapy → reduce dependence on chemotherapy/radiotherapy.

  • India, as a vaccine hub, could collaborate for affordable large-scale rollout.

  • Barriers: cost, infrastructure, regulatory approvals.

👉 Bottom Line: Enteromix represents a bold step in personalized immuno-oncology. While promising, global validation and larger trials are essential before clinical adoption.

✅ Conclusion

  • Cancer vaccines are a fast-evolving frontier in oncology.

  • Preventive vaccines (HPV, HBV) → already saving lives worldwide.

  • Therapeutic vaccines (Sipuleucel-T, neoantigen/mRNA vaccines) → rapidly advancing but still under evaluation.

  • Enteromix (Russia, 2025) has generated excitement but requires careful global validation.

  • With the momentum of mRNA and personalized medicine, the next decade may witness cancer vaccines as mainstream therapy alongside immunotherapy and precision oncology.   


📘 Prepared by Dr. Sk Sabir Rahaman
📍 Specialist Family Physician | Consultant Pharmacologist | Lifestyle & Diabetes Expert

🌐 Visit My Website for Full Article & other Free PDFs and Resources

Comments

Post a Comment